Abbvie Inc

ABBV

$106.70

+17.51% (1 year change)

Avg closing price

Price range

Market Cap

$185 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$12.9 Billion

Total revenue in the last quarter.

Net Income

$2.29 Billion

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$4.58

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$4.75 (4.53%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

25.32x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$3.3 Billion

Earnings before interest expenses and taxes in the last quarter.

Employees

0

The number of full time employees.

Revenue & Earnings

Balance Sheet

News

AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus

AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus

The crown jewel of AbbVie's big-dollar acquisition of Allergan, Botox is one of the most recognizable brands in pharma — and both drugmakers have worked overtime to protect its advantage. After sco...

Endpoints News Endpoints News, 16 days ago
Global Uveitis treatment Market (2020 to 2026) - Featuring AbbVie, Allergan and Bausch Health Companies Among Others - ResearchAndMarkets.com

Global Uveitis treatment Market (2020 to 2026) - Featuring AbbVie, Allergan and Bausch Health Companies Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Uveitis treatment Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The global uveitis treatment market is projected to witness cons...

Business Wire Business Wire, 17 days ago
AbbVie shares continue to trade in a bull market after better than expected Q4 results | Invezz

AbbVie shares continue to trade in a bull market after better than expected Q4 results | Invezz

AbbVie (NYSE: ABBV) shares weakened last week by more than 3%, and the current price stands around $104. According to analysts, it’s not hard to find reasons to invest in AbbVie, and as long the pr...

Invezz Invezz, 22 days ago